MN/CA IX/CA9 and renal cancer prognosis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7838240
SERIAL NO

12321506

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and/or extent of a MN/CA9 gene expression product in a sample from the affected subject, wherein if 50% or fewer cells are found to express the MN/CA9 gene, then the subject is considered to have a poorer prognosis. MN/CA9 gene expression products useful in the prognostic methods include MN protein, MN polypeptide and/or MN nucleic acids. The methods are useful as an aid in the selection of treatment for a patient with renal cell carcinoma, alone or in combination with conventional tumor stage and/or grade information. The methods of the invention can be used, for example, to identify those patients requiring more aggressive therapy regimens, or those patients most likely to respond to adjuvant immunotherapies, particularly MN/CA IX/CA9-targeted therapies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BIOMEDICAL RESEARCH CENTRE OF THE SLOVAK ACADEMY OF SCIENCESDÚBRAVSKA CESTA 9 BRATISLAVA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Erdo{hacek, over (g)}an Seyda Adana, TR 2 75
Soyupak, Bülent Adana, TR 1 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation